Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Revenues up 4% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

2Q Revenues: $18.5 billion (+4%)

2Q Earnings: $4.0 billion (-12%)

YTD Revenues: $36.0 billion (+2%)

YTD Earnings: $8.5 billion (-4%)

Comments: Worldwide Pharmaceutical sales were $8.7 billion for quarter, up 9% with domestic sales up 13% and international sales up 3%. Growth was driven by newer products including IMBRUVICA (up 92% to $295 million), XARELTO (up 26% to $594 million), INVOKANA/INVOKAMET (up 20% to $383 million), and ZYTIGA (up 10% to $601 million). New product sales growth was negatively impacted by lower sales of OLYSIO/SOVRIAD, down 84% to $43 million due to competitive entrants. STELARA sales were $804 million, up 41%. SIMPONI/SIMPONI ARIA sales were $448 million, up 46%. REMICADE sales were $1.8 billion, up 7%. Worldwide Consumer sales were $3.4 billion for the quarter, down 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters